In general, the use of specific therapeutic modalities to enhance THSD7B expression (e.g., material carrier-targeted delivery of THSD7B agonists, etc.)holds great promise for tumor-targeted therapy and has clinical translational value (67, 68). Here, THSD7B is linked to neoplasm.